Back to Market返回行情

NRXS NeurAxis, Inc.

USHealthcare
$7.15-0.90%OpenMarket Cap: $88.5M

As of 2026-07-10 14:38

Why NRXS matters now

NeurAxis, Inc. (NRXS) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.15 with -0.90% on the session and $88.5M in market capitalization; recent performance reads 1-month -1.38% and YTD +57.49%.

The latest financial table shown here is Q1 2026, with revenue of $1.6M, net income of $-1.8M, and EPS of $-0.18. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.9%.

The latest indexable market news headline is "NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript" from Seeking Alpha.

Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes Aharon Gil filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

13.62

P/S

20.68

EV/EBITDA

-11.50

DCF Value

$-5.05

FCF Yield

-6.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

85.0%

Operating Margin

-169.9%

Net Margin

-170.1%

ROE

-185.7%

ROA

-83.3%

ROIC

-119.2%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$1.6M$-1.8M$-0.18
Q4 2025$968.1K$-1.7M$-0.16
FY 2025$3.6M$-7.8M$-0.95
Q3 2025$811.4K$-2.1M$-0.24

Analyst Ratings

Consensus

Buy

Target (Consensus)

$8.00

Target (Median)

$8.00

Target Range

$8.00 - $8.00

Strong Buy: 0Buy: 2Hold: 0Sell: 0Strong Sell: 0
Craig-HallumBuy
2026-03-20
Craig-HallumBuy
2025-12-22

Trading Activity

Insider Trades

Aharon Gildirector
Sell2026-04-30
Aharon Gildirector
Sell2026-04-30
Carrico Brian Allendirector, officer: Chief Executive Officer
Buy2026-04-03
Carrico Thomas Joesephofficer: CRO, CCO, CPO
Buy2026-04-03
Henrichs Timothy Robertofficer: Chief Financial Officer
Buy2026-04-03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.41

NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.